USA – Triumvira Immunologics, an Austin, TX-based clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, completed an extension of its Series A financing, bringing the total round to approximately $100m.
The Series A extension featured new investors, including significant participation from B Capital Group, along with ATEM Capital, the Myeloma Investment Fund, the Multiple Myeloma Research Foundation’s venture philanthropy subsidiary, and others, joined by significant participation from existing investors, Leaps by Bayer, the impact investment unit of Bayer AG, and Northpond Ventures.The proceeds of the financing will support the continued preclinical and clinical development of Triumvira’s T cell Antigen Coupler (TAC)-T cell therapy programs. Led by Paul Lammers, M.D., M.Sc., President and CEO, Triumvira Immunologics is a clinical-stage company developing non-gene edited, first-in-class targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors. The company’s proprietary T cell Antigen Coupler (TAC) technology is a versatile platform that activates natural T cell functions differently from cell therapies such as CAR-T and engineered T cell receptor (TCR) therapies. The lead program, TAC01-HER2, is currently being evaluated in a Phase 1/2 clinical trial for patients with HER2-overexpressing solid tumors (TACTIC-2), including breast, gastric, ovarian, pancreatic, gall bladder and non-small cell lung cancers.Triumvira is headquartered in Austin, Texas with research facilities in Hamilton, Ontario.21/03/2022
